Cancer drug could help patients with low platelet disorder

NCT ID NCT05599880

Recruiting now Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug bortezomib in 29 adults with relapsed or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive bortezomib injections over three weeks for three cycles, then are followed for a year. The goal is to see if the drug can safely raise platelet counts to safer levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bortezomib
What this could lead to: If successful, bortezomib could offer a new treatment option for people with immune thrombocytopenia that hasn't responded to other therapies.
What could go wrong: This is a small, early-phase trial with only 29 participants. It may not work for everyone, and bortezomib can cause side effects like nerve damage and low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY IMMUNE THROMBOCYTOPENIA

Contacts and locations

Locations

SMG-SNU Boramae Medical Center
RECRUITING

Seoul, 07061, South Korea
Seoul National University Bundang Hospital
RECRUITING

Guri-si, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Seoul National University Hospital
NOT_YET_RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.